Durable SARS-CoV-2 B cell immunity after mild or severe disease

Selection of study participants

B cells were obtained from participants with mild COVID-19 disease, moderate to severe disease, and from healthy COVID-19 negative controls (Table 1). Participants with mild COVID-19 disease who never required hospitalization or supplemental oxygen were identified in a previously described cohort of ambulatory patients (28). Symptoms in this cohort were tracked using a FLU-PRO score calculated from a participant survey, as previously described (28). To ensure that participants with mild disease were included in this study, a group of seven participants was selected with a median peak FLU-PRO score below the median peak score for the entire ambulatory cohort (FLU-PRO median (range)=0.09 (0.0-0.38) vs. 0.25 (0.0-1.63)). Seven additional participants with moderate to severe COVID-19 disease were selected from a second cohort of hospitalized patients (29), matched with the mild disease participants based on time since onset of symptoms at the time of blood sampling (median (range) time since symptom onset in days: ambulatory=61 (45-68); hospitalized=46 (39-104)). Peak supplemental oxygen support in hospitalized participants ranged from 2L via nasal cannula to mechanical ventilation. At the time of blood sampling for this study, five of the hospitalized participants had been discharged, and two remained hospitalized with critical illness. Hereafter, ambulatory, hospitalized, and healthy groups will be referred to as “mild”, “severe”, and “healthy”, respectively.

Quantitation of S-RBD-specific B cells

A flow cytometry antibody panel was designed to identify non-class switched B cells (CD3-, CD19+, IgD/IgM+), class switched memory B cells (MBC) (CD3-, CD19+, IgM-, IgD-, CD38+/− (excluding ++), CD138-) and class switched antibody secreting cells (ASC) (CD3-, CD27+, CD19+/−, IgM-, IgD-, CD38++) (Supp. Figure 1). The frequency of all non-class switched B cells, class switched MBC, or class switched ASC among single viable lymphocytes was not significantly different between healthy, mild, and severe groups, but there was a trend toward greater frequency of class-switched ASC in the severe group compared to mild and healthy groups (Figure 1A). As we defined these three B cell populations, we used a 6x-histidine tagged, soluble S-RBD protein followed by anti-His Alexa Fluor 647-conjugated antibody to stain cells expressing S-RBD-specific antibodies on their surface (Figure 1B and Supplemental Figure 1). We quantitated the frequency of these S-RBD-specific cells among non-class switched B cells, class switched ASC, and class switched MBC (Figure 1C). Four of seven (57%) mild and seven of seven (100%) severe participants had a frequency of S-RBD-specific non-class switched B cells above the true positive threshold set using the healthy group. The frequency of these cells did not differ significantly between the mild and severe groups. Four of seven (57%) mild and four of seven (57%) severe participants had a frequency of S-RBD-specific class switched ASC above the true positive threshold. The frequency of these cells also did not differ significantly between the mild and severe groups. Six of seven (86%) mild and seven of seven (100%) severe participants had a frequency of S-RBD-specific class switched MBC above the true positive threshold. The single individual without detectable S-RBD-specific class switched MBC was asymptomatic throughout infection (peak FLU-PRO=0.0). Frequency of S-RBD-specific class switched MBC was significantly higher in severe participants than in mild participants (mean S-RBD+ frequency 0.85% vs. 0.20%, p=0.004). Taken together, these data demonstrate that S-RBD-specific cells could be detected among non-class switched B cells and class switched ASC in most SARS-CoV-2-infected participants, and S-RBD-specific class switched MBC could be detected in thirteen of fourteen participants. S-RBD-specific cells were significantly more frequent among class switched MBC from the severe group relative to the mild group.

• Download figure
• Open in new tab

Figure 1. Quantifying S-RBD specific B cells.

(A) % of lymphocytes that are class switched MBC, class switched ASC, or non-class switched B cells in healthy, mild, and severe participants (N=7 for each group). (B) Gating strategy for S-RBD specific non-class switched B cells (CD3-, CD19+, IgD/IgM+, S-RBD+), S-RBD specific class switched MBC (CD3-, CD19+, IgM-, IgD-, CD38+/− (excluding ++), CD138-, S-RBD+), and S-RBD specific class switched ASC (CD3-, CD19+/−, IgM-, IgD-, CD38++, CD27+, S-RBD+) in “healthy” (COVID-19 negative), “mild” (COVID-19+, ambulatory), and “severe” (COVID-19+, hospitalized) participants. (C) % of class switched MBC, class switched ASC, and non-class switched B cells that are S-RBD specific in healthy, mild, and severe participants (N=7 for each group). Dotted line represents the true positive threshold, defined as the mean plus two standard deviations of the healthy group. For A and C box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Three group comparisons in A were performed using one-way ANOVA, with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Two group comparisons in C were performed with t tests if data were normally distributed based on Shapiro Wilk normality test or Mann Whitney test if data were not normally distributed. Statistically significant comparisons are indicated (** P ≤ 0.01)

Detectable S-RBD-specific MBC despite low levels of anti-S-RBD IgG and neutralizing antibodies in plasma

Given concerns that low or waning plasma titers of neutralizing antibodies in some individuals indicate a lack of a durable humoral response, we were interested in evaluating whether COVID-19 participants with low levels of plasma anti-S-RBD IgG and low neutralizing antibody levels had detectable S-RBD-specific MBC in circulation. S-RBD binding IgG was measured using serial dilutions of plasma in an ELISA, and neutralizing antibodies were measured with serial dilutions of plasma in a microneutralization assay using replication competent SARS-CoV-2 virus (10). Curves were fit to these data, and area under the curve (AUC) values calculated. Anti-S-RBD IgG and neutralization AUC values each varied over a wide range across study subjects (1e2.7-1e4.9 and 1e0.8-1e3.0, respectively). As expected based on prior studies (3, 10), there was a trend toward higher anti-S-RBD IgG and neutralization AUC values in the severe group relative to the mild group, although these differences were not statistically significant, likely due to the small number of subjects (Figure 2A-B). We next evaluated whether we could detect S-RBD-specific cells among class switched MBC of participants with low, intermediate, or high levels of plasma anti-S-RBD IgG (Figure 2C) or low, intermediate, or high levels of neutralizing antibodies (Figure 2D). We detected S-RBD-specific class switched MBC above the nonspecific background frequency in 4 of 5 participants with the lowest IgG and neutralization AUCs, 5 of 5 with intermediate AUCs, and 4 of 4 with highest AUCs. The single individual without detectable S-RBD-specific class switched MBC had the lowest levels of plasma anti-S-RBD IgG (AUC=1e2.7) and neutralizing antibodies (AUC=1e0.8) in the study. There was a non-significant trend toward higher frequencies of RBD specific cells among class switched MBC in the higher AUC IgG and higher neutralizing antibody AUC groups relative to the lowest AUC groups. Overall, these data show that S-RBD-specific class switched MBC were detectable in the circulation of most infected individuals, including the majority of subjects with low levels of plasma anti-S-RBD IgG and neutralizing antibodies.

• Download figure
• Open in new tab

Figure 2. Comparisons of serum anti S-RBD IgG and neutralizing antibody titers in mild and severe participants.

(A) Anti S-RBD IgG area under the curve (AUC) in mild and severe participants. (B) Neutralizing antibody AUC in mild and severe participants. (C) % of class switched MBC that are RBD specific, from participants with plasma anti-S-RBD AUC values in the lowest, middle, and highest tertiles. (D) % of class switched MBC that are RBD specific, from participants with plasma neutralizing antibody AUC values in the lowest, middle, and highest tertiles. Dotted line represents the true positive threshold, defined as the mean plus two standard deviations of the healthy group. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. P values for A-B were calculated using t tests and P values for C-D were calculated using one-way ANOVA test for linear trend. No statistically significant comparison was found.

UMAP analysis of class switched MBC surface markers

To further characterize the phenotypes of S-RBD-specific and nonspecific class switched MBC in healthy, mild, or severe COVID-19 patients, we studied surface expression of CD21, CD27, FCRL5, CXCR5, CD22, BTLA, and CD38. CD21 and CD27 expression allow separation of MBC into intermediate MBC (intMBC, CD21+ CD27-), resting MBC (rMBC, CD21+, CD27+), activated MBC (actMBC, CD21-CD27+), and atypical MBC (atyMBC, CD21-CD27-) subsets. B- and T-lymphocyte attenuator (BTLA) or CD272 and CD22/Siglec2 are immune cell inhibitory receptors with cytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIMs) (30-33), while FCRL5 has two ITIMs and one immunoreceptor tyrosine-based activation motif (ITAM) (34, 35). C-C chemokine receptor type 5 (CXCR5) is a germinal center homing receptor that is generally down-regulated after cells have undergone class switching and somatic hypermutation (36, 37). CD38 has relatively undefined functional significance, but it is negative on “late” class-switched MBC and positive on “early” class switched MBC that emerged more recently from germinal center reactions (38).

We first analyzed a UMAP projection of all class switched MBC from healthy, mild, and severe groups generated based on binding of S-RBD and expression of CD21, CD27, CD38, CD22, FCRL5, CXCR5, and BTLA (Figure 3A). This UMAP identified a clear segregation of co-mingled mild and severe S-RBD+ cells from RBD- and healthy donor cells. From this UMAP clustering projection, we extrapolated multigraph color mapping of the receptors with observed differential expression of all surface markers except BTLA (Figure 3B). To determine whether there was any shift in expression of these markers between study groups, we overlayed expression histograms of all the surface receptors of healthy, mild S-RBD-, mild S-RBD+, severe S-RBD-, and severe S-RBD+ class switched MBC (Figure 3C). Again, there was no observable shift in the expression of BTLA. For all study groups, there was a bimodal distribution of CD21 expression, indicating that both CD21+ (intMBC and rMBC) and CD21-(actMBC and atyMBC) MBC subsets were present. For both mild and severe S-RBD+ MBC, we observed a shift toward increased expression of CD22 and FCRL5 and downregulation of CXCR5 compared to healthy and S-RBD-populations. For CD38, we observed upregulation in mild and severe S-RBD+ MBC and downregulation in mild and severe S-RBD-MBC compared to healthy participants.

• Download figure
• Open in new tab

Figure 3: UMAP and histogram expression profiles of surface receptors on class switched MBC.

(A) Concatenated class switched MBC from healthy, mild, and severe subjects projected as UMAP with gated S-RBD+ class switched B cells. (B) Multigraph color mapping of the UMAP projection of S-RBD, CD21, CD27, CD38, FcRL5, CD22, CXCR5, and BTLA. (C) Overlay histograms comparing the expression of FCRL5, CD22, CXCR5, BTLA, CD21, CD27, and CD38 in S-RBD- or S-RBD+ healthy, mild and severe groups.

Quantifying subsets of S-RBD nonspecific and S-RBD-specific class switched MBC

To better understand the functional phenotypes of the S-RBD-specific MBC identified in both mild and severe groups, we compared the frequencies of intMBC, rMBC, actMBC, and atyMBC among S-RBD-specific and S-RBD nonspecific class switched MBC at the level of individual participants (Figure 4). MBC subsets identified based on CD21 and CD27 expression have notably different phenotypes (38). Classical MBC, also called rMBC, persist for months to years and respond to antigen re-challenge by proliferating and differentiating into antibody-producing ASC. ActMBC are cells that recently left germinal centers and are already primed to become antibody secreting plasma cells (39). AtyMBC are generally thought to be poorly functional, and are present at higher frequencies in chronic infections like HIV-1, hepatitis C virus, tuberculosis, or malaria (25, 40, 41). AtyMBC were also found to be more frequent among bulk (not antigen specific) MBC during acute SARS-CoV-2 infection (42). IntMBC likely represent a transitional state between MBC subsets.

• Download figure
• Open in new tab

Figure 4: Frequency of MBC subsets in S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RB-D+) class switched MBC from healthy, mild, or severe participants.

(A) intMBC (CD21+, CD27-). (B) rMBC (CD21+, CD27+). (C) actMBC (CD21-, CD27+). (D) atyMBC (CD21-, CD27-). For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* P ≤ 0.05).

S-RBD-specific class switched MBC from two participants were not included in these or subsequent analyses, either because they did not have detectable S-RBD-specific class switched MBC frequency above background (subject M5), or because absolute cell numbers were low given severe lymphopenia (subject S3). S-RBD nonspecific MBC were adequately abundant in all participants to allow their inclusion in all analyses (see Methods). There were no statistically significant differences in the frequencies of intMBC, rMBC, or atyMBC subsets among S-RBD-specific or S-RBD nonspecific class switched MBC from healthy, mild or severe participants (Figure 4). In contrast, actMBC were significantly more frequent among both S-RBD nonspecific and S-RBD-specific MBC populations in severe participants compared to healthy and mild participants (e.g. mean frequency of severe S-RBD+ MBC vs. healthy S-RBD-MBC, 16.09% vs. 5.53%, p=0.01) (Figure 4C). This likely represents greater ongoing immune activation in the severe infection group relative to the healthy and mild groups and is also consistent with the observed trend toward higher frequency of ASC in the severe group (Figure 1A). Overall, these data demonstrate an expected distribution of S-RBD-specific cells among MBC subsets, with the largest proportion of S-RBD-specific class switched MBC in both mild and severe groups falling in the rMBC subset.

Expression of activating or inhibitory surface markers on class switched MBC and MBC subsets

To further investigate the differential expression of surface markers that we observed in the UMAP projections and histograms of grouped samples, we compared expression of FCRL5, CXCR5, CD22, and CD38 at the level of individual participants between healthy, mild S-RBD-, mild S-RBD+, severe S-RBD-, and severe S-RBD+ groups (Figure 5). BTLA expression was not included in this analysis given no differential expression in the UMAP. We found that FCRL5 was dramatically upregulated in mild S-RBD+ MBC relative to healthy cells, mild S-RBD-cells, and severe S-RBD+ cells (p=<0.0001, 0.003, and 0.01, respectively). FCRL5 was also upregulated to a lesser, but still significant extent on severe S-RBD+, mild S-RBD-, and severe S-RBD-MBC relative to healthy MBC (p=0.01, 0.03, and 0.04, respectively) (Figure 5A). The frequency of CXCR5+ cells among class switched MBC was not significantly different between the groups, although it was downregulated in 3 of 6 participants in both mild and severe groups (Figure 5B) which could account for the shift observed in the histogram in Figure 3C. Since CD22/siglec-2 is ubiquitously expressed on B cells, we analyzed its relative expression by comparing mean fluorescence intensities (MFI). Compared to healthy controls, CD22 was upregulated on mild S-RBD+ class switched MBC (p=0.04) (Figure 5C). Among class switched MBC, CD38 expression did not differ significantly between SARS-CoV-2 infected and healthy participants (Figure 5D).

• Download figure
• Open in new tab

Figure 5: Surface expression of FcRL5, CXCR5, CD22, and CD38 on S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RBD+) class switched MBC from healthy, mild, or severe participants. Expression is shown as either percent of cells positive or the mean fluorescent intensity (MFI).

(A) FcRL5 (B) CXCR5 (C) CD22 (D) CD38. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001).

Having observed upregulation of both FCRL5 and CD22, a trend toward downregulation of CXCR5, and a trend toward upregulation of CD38 on S-RBD+ class switched MBC, we analyzed expression of these surface markers on MBC subsets rMBC, intMBC, actMBC, and atyMBC (Figure 6). As with total class switched RBD+ MBC, we found that FCRL5 was dramatically upregulated on mild S-RBD+ rMBC relative to healthy rMBC, mild S-RBD-rMBC, and severe S-RBD+ rMBC (p=<0.0001, <0.0001, and <0.0001, respectively). FCRL5 was also upregulated to a lesser, but still significant extent on severe S-RBD+ and mild S-RBD-rMBC relative to healthy rMBC (p=0.02 and 0.01, respectively). CXCR5 was significantly downregulated on mild S-RBD+ atyMBC relative to healthy atyMBC, mild S-RBD-atyMBC, and severe S-RBD+ atyMBC (p=0.001, 0.003, and 0.001, respectively). CD22 was significantly upregulated on mild S-RBD+ rMBC and intMBC relative to healthy cells (p=0.02 and 0.03, respectively). CD38+ cells were significantly more frequent among mild S-RBD+ actMBC relative to healthy actMBC and mild S-RBD-actMBC (p=0.007 and 0.01, respectively). Taken together, these results indicate that FCRL5 was significantly upregulated on S-RBD-specific rMBC in both mild and severe infection. In mild but not severe infection, CD22 was upregulated on S-RBD-specific rMBC and intMBC, CXCR5 was downregulated on S-RBD-specific atyMBC, and CD38 was upregulated on S-RBD-specific actMBC.

• Download figure
• Open in new tab

Figure 6: Surface expression of FcRL5, CXCR5, CD22, and CD38 on S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RBD+) class switched intMBC, rMBC, actMBC, or atyMBC from healthy, mild, or severe participants. Expression is shown as either percent of cells positive or the mean fluorescent intensity (MFI).

(A) FcRL5 (B) CXCR5 (C) CD22 (D) CD38. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001).

Study participants

Participants with mild COVID-19 disease who never required hospitalization or supplemental oxygen were identified in a cohort of ambulatory COVID-19 patients. Symptoms in this cohort were tracked using a FLU-PRO score calculated from a participant survey, as previously described (28). Participants with moderate to severe COVID-19 disease were selected from a cohort of hospitalized patients (29), matched with the mild participants based on time since onset of symptoms at the time of blood sampling. PBMC cryopreserved prior to the onset of the COVID-19 pandemic were also obtained from anonymous healthy blood donors. Healthy and COVID-19 participant blood specimens were ficoll gradient separated into plasma and PBMCs. PBMCs were viably cryopreserved in FBS + 10% DMSO for future use.

Expression and purification of soluble Spike protein Receptor Binding Domain (S-RBD)

Measurement of endpoint anti-S-RBD IgG titer

The protocol was adapted from a published protocol from Dr. Florian Krammer’s laboratory (Stadlbauer 2020). Ninety-six well plates (Immulon 4HBX, Thermo Fisher) were coated with S-RBD at a volume of 50 μl of 2 μg/ml of diluted antigen in filtered, sterile 1xPBS (Thermo Fisher) at 4°C overnight. Coating buffer was removed, plates were washed three times with 300 μl of PBS-T wash buffer (1xPBS plus 0.1% Tween 20, Fisher Scientific), and blocked with 200 μl of PBS-T with 3% non-fat milk (milk powder, American Bio) by volume for one hour at room temperature. All plasma samples were heat inactivated at 56°C on a heating block for one hour prior to use. Negative control samples were prepared at 1:10 dilutions in PBS-T in 1% non-fat milk and plated at a final concentration of 1:100. A monoclonal antibody (mAb) specific for the SARS-CoV-2 spike protein was used as a positive control (1:5,000, Sino Biological). For serial dilutions of plasma on S-RBD coated plates, plasma samples were prepared in three-fold serial dilutions starting at 1:20 in PBST in 1% non-fat-milk. Blocking solution was removed and 10 μl of diluted plasma was added in duplicates to plates and incubated at room temperature for two hours. Plates were washed three times with PBS-T wash buffer and 50 μl secondary antibody was added to plates and incubated at room temperature for one hour. Anti-human secondary antibodies used included Fc-specific total IgG HRP (1:5,000 dilution, Invitrogen), prepared in PBS-T plus 1% non-fat milk. Plates were washed and all residual liquid removed before adding 100 μl of SIGMAFAST OPD (o-phenylenediamine dihydrochloride) solution (Sigma Aldrich) to each well, followed by incubation in darkness at room temperature for ten minutes. To stop the reaction, 50 μl of 3M hydrochloric acid (HCl, Fisher Scientific) was added to each well. The OD of each plate was read at 490nm (OD490) on a SpectraMax i3 ELISA plate reader (BioTek). The positive cutoff value for each plate was calculated by summing the average of the negative values and three times the standard deviation of the negatives. All values at or above the cutoff value were considered positive. Values were graphed on a dose response curve, a best fit line drawn by nonlinear regression, and area under the curve (AUC) calculated.

Measurement of endpoint neutralization titer

Plasma neutralization titers were determined as described for SARS-CoV (Schaecher 2008). Two-fold dilutions of plasma (starting at a 1:20 dilution) were made in IM. Infectious virus was added to the plasma dilutions at a final concentration of 1×104 TCID50/ml (100 TCID50 per 100ul). The samples were incubated for one hour at room temperature, then 100 uL of each dilution was added to one well of a 96 well plate of VeroE6-TMPRSS2 cells in sextuplet for 6 hours at 37°C. The inoculums were removed, fresh IM was added, and the plates were incubated at 37°C for 2 days. The cells were fixed by the addition of 150 uL of 4% formaldehyde per well, incubated for at least 4 hours at room temperature, then stained with Napthol blue black. The nAb titer was calculated as the highest serum dilution that eliminated cytopathic effect (CPE) in 50% of the wells. Values were graphed on a dose response curve, a best fit line drawn by nonlinear regression, and area under the curve (AUC) calculated.

Cell staining and flow cytometry

PBMCs were isolated from blood using ficoll separation gradient and viably frozen. Cells were thawed before use, and 5e6-10e6 PBMCs were stained from each participant. Fc blocker (BD Cat #564220) diluted in FACS Buffer (1x PBS with 1% BSA) was added to the cells and incubated for 30minutes on ice or 4c. The cells were then washed twice with FACS buffer. Soluble 6X-His tagged S-RBD protein was then added to the cells and incubated at room temperature for 30 min. This was followed by wash steps with FACS buffer. Conjugated antibodies (Suppl. Table 1 for list of antibodies and their conjugate fluorophores) and live dead stain was then added to the cells and incubated for an additional 30min. The cells were washed two or three more times before running the cells on BD Biosciences LSR II instrument. 1e6-6e6 total events were collected for each participant, resulting in medians of 69.5 absolute RBD+ and 13,971 RBD-class switched MBC for each participant (range=1-454 RBD+, 152-84,645 RBD-MBC). For UMAP analysis, all RBD+ class switched MBC were included, and RBD-class switched MBC were downsampled to 3000 cells per subject. The subject with only 1 RBD+ cell was excluded from RBD+ MBC subset analyses. Positive gates for each fluorophore were set after compensation and using fluorescence minus one (FMO) staining and isotype control antibodies.

Statistical analysis

FlowJo software was used to analyze all the flow results from the LSRII. Statistical analyses were performed in Prism (Graphpad software). Two group comparisons were performed with t tests if data were normally distributed based on Shapiro Wilk normality test or Mann Whitney rank test if data were not normally distributed. Multi-group comparisons were performed using one-way ANOVA, with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method.

Study approval

This research was approved by the Johns Hopkins University School of Medicine’s Institutional Review Board (IRB). Prior to blood collection, all participants provided informed written consent.